Bruce Carlson[email protected]Lymphoid CancerAMP 2021 meeting puts spotlight back on cancerSeminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.November 22, 2021ConsumerDiabetes testing market poised for growthHowever, technological advances and increased knowledge of diabetes have led to two new areas driving the diabetes testing market: continuous glucose monitoring (CGM) and hemoglobin A1c (HbA1c) testing.November 1, 2021ConsumerLatin America's IVD market to reach $4.2 billion in 2025The forecast growth rate for Latin America will therefore slightly outpace what's expected for the the U.S., which is the largest IVD market at $41.3 billion and makes up approximately 40%-45% of the global IVD market.August 16, 2021Clostridium DifficileMarket for biomarker-based infectious disease tests to hit $15BBiomarkers include more than 1,000 substances that serve as reagents, consumables, and/or test components for a number of medical-related diagnostic and research applications. Substances that detect and measure genetic changes in patient samples are also included in the sales statistics.May 25, 2021ConsumerPOC test market reaches $29.3B as COVID-19 revenues boomIn addition, new technologies and increased demand contributed to growth in the markets. A contributing factor to slower growth in some segments was pricing strategies that continued to discount the cost of POC diagnostic testing in some segments and higher cost in other segments of testing.April 19, 2021COVID-19Market for COVID-19 diagnostics to hit $38B by year endAs of January 31, over 26 million cases of COVID-19 have been reported in the U.S., and more than 500,000 deaths. President Joe Biden has pledged a federally directed effort against the pandemic. Over 1 billion tests have been run for COVID-19 worldwide, according to the report.February 25, 2021Molecular DiagnosticsCOVID-19 testing boosts molecular point-of-care marketMolecular POC diagnostic solutions offer improvements in the sensitivity and specificity of existing near-patient and rapid tests while expanding the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world, and are used to assess conditions or admit patients. The concept of mPOC is to combine the accessibility of POC testing with the accuracy of molecular technology. Disclosure: LabPulse.com is a sister company of Kalorama Information.January 26, 2021InfectiousRoche sees alignment between COVID-19 tests, vaccines in 2021In the December 14 briefing, Roche executives focused on lessons learned from the global healthcare crisis. Participating in the discussion were Thomas Schinecker, CEO of the company's Roche Diagnostics division; Matt Sause, president and CEO of Roche Diagnostics North America; and Dr. William Morice, PhD, president of Mayo Clinic Laboratories, a customer of Roche.December 14, 2020Pathology, histology6 trends to watch at AACC 2020As usual, AACC 2020 is the largest gathering of lab professionals and the IVD vendors that service them. This year to keep their interest and participation, virtual happy hours and even ugly sweater parties are part of the meeting, along with scientific sessions and posters.December 13, 2020Immune System DiseasesVaccines won't eliminate the need for COVID-19 testingIt may be natural to suspect that if a vaccine is available, there will be fewer cases thus less reason to test. But this isn't normally the interplay between vaccines and diseases.November 23, 2020Previous PagePage 3 of 7Next PageTop StoriesGene silencing and gene editingEngineered Cas clears barrier to antiviral CRISPR therapiesResearchers have engineered a Cas enzyme to enhance activity against RNA viruses, resulting in a system that completely blocked the replication of various SARS-CoV-2 strains.Artificial IntelligenceAI-powered endoscope doubles detection of high-risk esophageal lesionsMergers & AcquisitionsBruker to acquire NanoString for $392.6MTrends and FinanceDermTech receives delisting warning from NasdaqSponsor ContentVisit our Molecular Diagnostics Community